A5020613063- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- Immune cells in cancer
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Cancer, Lipids, and Metabolism
- Cancer Mechanisms and Therapy
- Concrete and Cement Materials Research
- Phagocytosis and Immune Regulation
- Pancreatic and Hepatic Oncology Research
- Advanced Photocatalysis Techniques
- Liver Disease and Transplantation
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Magnesium Oxide Properties and Applications
- Hepatitis B Virus Studies
- Inflammatory Biomarkers in Disease Prognosis
- TiO2 Photocatalysis and Solar Cells
- Liver physiology and pathology
- Cancer-related molecular mechanisms research
- Colorectal Cancer Treatments and Studies
- Catalytic Processes in Materials Science
- Cancer Research and Treatments
Sun Yat-sen University Cancer Center
2016-2025
Sun Yat-sen University
2016-2025
State Key Laboratory of Oncology in South China
2016-2025
Dalian University
2025
Xi'an University of Architecture and Technology
2015-2024
China Southern Power Grid (China)
2024
Renmin University of China
2015-2024
South China University of Technology
2023-2024
Center for Discovery
2023
Chongqing University
2023
Purpose To compare radiofrequency ablation (RFA) with or without transcatheter arterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC). Patients and Methods A randomized controlled trial was conducted on 189 patients HCC less than 7 cm at a single tertiary referral center between October 2006 June 2009. were randomly asssigned to receive TACE combined RFA (TACE-RFA; n = 94) alone (n 95). The primary end point overall survival. secondary recurrence-free survival,...
To compare retrospectively the effects of percutaneous radiofrequency (RF) ablation with those hepatic resection in treatment hepatocellular carcinoma (HCC) measuring 2 cm or smaller.This study was approved by institutional ethics committee, and all patients provided written informed consent before treatment. From December 2003 to 2008, 145 a resectable HCC smaller were studied. Sixty-six had central (located at least 3 from liver capsule). As an initial treatment, 71 treated RF 74 surgical...
Cancer-associated fibroblasts (CAFs) are key players in multicellular, stromal-dependent alterations leading to HCC pathogenesis. However, the intricate crosstalk between CAFs and other components tumor microenvironment (TME) remains unclear. This study aimed investigate cellular among CAFs, cells, tumor-associated neutrophils (TANs) during different stages of pathogenesis.In HCC-TME, CAF-derived cardiotrophin-like cytokine factor 1 (CLCF1) increased chemokine (C-X-C motif) ligand 6 (CXCL6)...
Early metastasis is responsible for frequent relapse and high mortality of hepatocellular carcinoma (HCC), but its underlying mechanisms remain unclear. Epithelial-mesenchymal transition (EMT) has been considered a key event in metastasis. Based on histological examination serial HCC sections three-dimensional reconstruction, we found novel prevalent vascular pattern, vessels that encapsulated tumor clusters (VETC) formed cobweb-like networks. The presence VETC (VETC(+) ) predicted higher...
Abstract Aims The second Singapore Mental Health Study (SMHS) – a nationwide, cross-sectional, epidemiological survey - was initiated in 2016 with the intent of tracking state mental health general population Singapore. study employed same methodology as first 2010. SMHS aimed to (i) establish 12-month and lifetime prevalence correlates major depressive disorder (MDD), dysthymia, bipolar disorder, generalised anxiety (GAD), obsessive compulsive (OCD) alcohol use (AUD) (which included abuse...
In a previous phase II trial, hepatic arterial infusion chemotherapy (HAIC) with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) yielded higher treatment responses than transarterial chemoembolization (TACE) in large unresectable hepatocellular carcinoma. We aimed to compare the overall survival of patients treated FOLFOX-HAIC versus TACE as first-line this population.In randomized, multicenter, open-label adults carcinoma (largest diameter ≥ 7 cm) without macrovascular...
Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but prognosis still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and immune checkpoint inhibitors showed promising results carcinoma. Considering different anti-malignancy mechanisms, combining these three treatments may improve outcomes. This study aimed to compare efficacy safety of lenvatinib, toripalimab, plus HAIC versus lenvatinib carcinoma.This was a retrospective including...
Characterizing the compositional and phenotypic characteristics of tumor-infiltrating B cells (TIBs) is important for advancing our understanding their role in cancer development. Here, we establish a comprehensive resource human by integrating single-cell RNA sequencing data from 649 patients across 19 major types. We demonstrate substantial heterogeneity total abundance subtype composition observe immunoglobulin G (IgG)-skewness antibody-secreting cell isotypes. Moreover, identify...
To compare prospectively the effects of radiofrequency (RF) ablation after transcatheter arterial chemoembolization (TACE) with those RF alone in treatment recurrent hepatocellular carcinoma (HCC).This study was approved by institutional ethics committee, and all patients gave written informed consent. From January 2002 to December 2006, 139 HCC measuring 5 cm diameter or smaller were randomized receive either sequential TACE (sequential group, n=69) (RF n=70). The survival curves...
The long-term survival outcomes of hepatic resection (HR) compared with transcatheter arterial chemoembolization (TACE) for resectable hepatocellular carcinoma (HCC) portal vein tumor thrombus (PVTT) are unclear.Between December 2002 and 2007, 201 consecutive patients diagnosed HCC PVTT received HR as an initial treatment in our center. These were 402 case-matched controls selected from a pool 1798 (with 1:2 ratio) who TACE during the study period. was classified to 4 types: involving...
<h3>Background</h3> Accumulating studies suggest that targeting epigenetic modifications could improve the efficacy of tumor immunotherapy; however, mechanisms underlying this phenomenon remain largely unknown. Here, we investigated ability modifier, enhancer zeste 2 polycomb repressive complex subunit (EZH2), to regulate expression immune checkpoint inhibitor, programmed death-1 ligand 1 (PD-L1) in hepatocellular carcinoma (HCC). <h3>Methods</h3> Immunohistochemistry and multiplex...
Background An elevated preoperative neutrophil-to-lymphocyte ratio (NLR) has been reported to be a prognostic factor for hepatocellular carcinoma (HCC) patients after treatment. However, the clinical implication of postoperative NLR change remains unclear. Materials and Methods From May 2005 Aug 2008, cohort consecutive 178 small HCC treated with radiofrequency ablation (RFA) was retrospectively reviewed. The recorded within 3 days before 1 month RFA. Baseline characteristics, overall...
The optimal treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) remains controversial. We aimed to investigate the best patients HCC PVTT. From January 2002 2014, data from all consecutive PVTT who underwent surgical (ST),TACE,TACE combined sorafenib (TACE-Sor), or TACE radiotherapy (TACE-RT) in 4 largest tertiary hospitals China were analyzed retrospectively. divided into 3 subtypes according extent of (type I-III). primary endpoint was overall survival (OS)....
// Shan-Shan Jiang 1, * , Yan Tang Yao-Jun Zhang 2, De-Sheng Weng 1 Zhong-Guo Zhou 2 Ke Pan Qiu-Zhong Qi-Jing Wang Qing Liu Jia He Jing-Jing Zhao Li Min-Shan Chen Alfred E. Chang 3 Qiao Jian-Chuan Xia Department of Biotherapy, Sun Yat-sen University Cancer Center, State Key Laboratory Oncology in South China, Collaborative Innovation Center for Medicine, Guangzhou, China Hepatobiliary Oncology, Michigan Comprehensive Ann Arbor, Michigan, USA These authors have contributed equally to this...